Product :
DCC-2036 Rebastinib
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
| Product name：DCC-2036 Rebastinib |
Purity：98% min |
| CAS NO：1020172-07-9 |
Solubility：DMSO : ≥ 320 mg/mL (578.05 mM) |
| Molecular Formula：C30H28FN7O3 |
Package：Package according to customer requirements |
| Molecular Weight：553.587 |
Storage：Store at -20℃ |
Remarks
Rebastinib, also known as DCC-2036, is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor DCC-2036 binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Multitargeted tyrosine kinase inhibitor DCC-2036 may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors